Status:
COMPLETED
Amniotic Fluid Ischemia Modified Albumin as a Novel e Prenatal Diagnostic Marker for Down Syndrome
Lead Sponsor:
Karadeniz Technical University
Conditions:
Down Syndrome
Prenatal Stress
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Down syndrome is the most common genetic disorder in the society that causes mental retardation. Today, screening tests (combined test, triple screening, ultrasonography and age) are performed for the...
Detailed Description
The alpha feto protein level showing liver function is lower in babies with Down syndrome and this biochemical marker is one of the basic parameters of triple screening. If these babies have insuffic...
Eligibility Criteria
Inclusion
- 20 cases diagnosed with down syndrome in the Duzen laboratory chromosome culture
- 74 cases which are normal in the Duzen laboratory chromosome culture
Exclusion
- \- absent
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT04293380
Start Date
March 1 2012
End Date
September 1 2016
Last Update
December 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karadeniz Technical Universty Medical School
Trabzon, Turkey (Türkiye), 61100